JNJ-26481585, also known as JNJ26481585 or Quisinostat, is a small molecule inhibitor of histone deacetylase (HDAC), which is an enzyme involved in the regulation of gene expression through chromatin modification. It was first discovered in 2008 and has since been studied for its potential as a treatment for various types of cancer.
The chemical name for JNJ-26481585 is N-hydroxy-2-(2-methyl-1H-indol-4-yl)thiazole-4-carboxamide.
The molecular formula of JNJ-26481585 is C14H12N4O2S.
The formula weight of JNJ-26481585 is 308.34 g/mol.
The CAS number of JNJ-26481585 is 875320-29-9.
Top ten keywords from Google and Synonyms:
- JNJ-26481585 clinical trials
- JNJ-26481585 mechanism of action
- JNJ-26481585 cancer treatment
- JNJ-26481585 pharmacokinetics
- JNJ-26481585 toxicity
- JNJ-26481585 side effects
- JNJ-26481585 synthesis
- Histone deacetylase inhibitor JNJ-26481585
- HDAC inhibitor Quisinostat
- HDAC inhibitor Quisinostat
Health benefits of this product:
JNJ-26481585 has been primarily developed for the treatment of cancer. As an HDAC inhibitor, it is thought to regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription.
Some potential effects of JNJ-26481585 include:
- Inhibition of tumor growth
- Reduction of cancer cell proliferation
- Induction of apoptosis (programmed cell death)
- Sensitization of cancer cells to other therapies
JNJ-26481585 works by inhibiting HDAC, which is an enzyme involved in the regulation of gene expression through chromatin modification. By inhibiting HDAC, JNJ-26481585 can promote acetylation of histones, leading to changes in chromatin structure and gene transcription.
JNJ-26481585 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with JNJ-26481585.
JNJ-26481585 can cause several side effects in some patients. These can include:
The optimal dosing regimen of JNJ-26481585 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 10 to 100 mg/kg. In clinical trials, doses ranged from 20 to 50 mg once daily. The drug is typically administered orally.
JNJ-26481585 is a small molecule inhibitor of HDAC that has shown potential as a treatment for various types of cancer. By inhibiting HDAC, JNJ-26481585 may regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of JNJ-26481585 in treating various types of cancer.